Avity Investment Management Inc. Has $27.59 Million Stock Holdings in Amgen Inc. $AMGN

Avity Investment Management Inc. lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.3% during the second quarter, HoldingsChannel.com reports. The firm owned 76,186 shares of the medical research company’s stock after purchasing an additional 3,807 shares during the period. Amgen accounts for 1.8% of Avity Investment Management Inc.’s portfolio, making the stock its 24th biggest position. Avity Investment Management Inc.’s holdings in Amgen were worth $27,588,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after buying an additional 114 shares during the last quarter. Schnieders Capital Management LLC. increased its holdings in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after buying an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC raised its position in Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after acquiring an additional 416 shares in the last quarter. Finally, Ieq Capital LLC raised its position in Amgen by 5.1% during the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after acquiring an additional 2,611 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Truist Financial raised their target price on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research note on Wednesday. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Bank of America upped their price objective on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday. Wells Fargo & Company raised their price target on Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, Morgan Stanley raised their price objective on shares of Amgen from $333.00 to $351.00 and gave the stock an “equal weight” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $370.07.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Trading Up 1.5%

Shares of AMGN stock opened at $410.95 on Friday. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.01 and a current ratio of 1.37. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $418.40. The company has a market cap of $222.17 billion, a PE ratio of 25.54, a P/E/G ratio of 3.83 and a beta of 0.41. The stock’s fifty day moving average price is $362.77 and its two-hundred day moving average price is $356.24.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the prior year, the company earned $6.02 EPS. Amgen’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts predict that Amgen Inc. will post 22.78 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.